StockWatch
·

PRAJ INDUSTRIES LTD.

BSE: 522205

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
674.15
+18.6%-3.2%
Expenditure
611.46
+15.0%-4.6%
Net Profit
45.43
+78.6%+9.1%
OPM %
8.06%
+4.28pp-0.71pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00211.62423.25634.87846.50Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Orders Strong, Revenue Flat: GenX Execution Now Defines the Margin Story

GenX capex · order-revenue lag · margin recovery

Result verdictFollow-upQ2 FY2703 Nov 20266 minIndustrials & Infra

Growth delayed, margins bottoming; GenX execution critical

GenX breakeven · CBG JV early stage · International pipeline ₹1000 Cr

TranscriptDeep diveQ2 FY2703 Nov 20266 minIndustrials & Infra

Praj Q2 FY27: consolidated PAT +20% YoY to ₹23 Cr, core margin eases on flat revenue

process engineering · ethanol equipment · margin compression

ResultsQ2 FY2729 Oct 20263 minIndustrials & Infra
Latest
Quarterly Result29 Oct, 4:13 pm

Praj Q2 FY27: consolidated PAT +20% YoY to ₹23 Cr, core margin eases on flat revenue

Praj Industries' consolidated (primary basis) Q2 FY27 revenue was ₹849.0 Cr, up a marginal 0.9% YoY from ₹841.6 Cr — essentially flat, not a growth quarter. Consolidated PAT rose 20.1% YoY to ₹23.2 Cr from ₹19.3 Cr, with EPS at ₹1.26 versus ₹1.05 a year ago. Sequentially both lines look stronger (revenue +18.6% QoQ, PAT roughly doubling QoQ) but that is a weak-base effect off a soft Q1 FY27 (₹11.6 Cr PAT) rather than a trend, and YoY is the number that should anchor the read. Standalone tells a materially different story: standalone revenue actually fell 5.0% YoY to ₹651.9 Cr even as standalone PAT grew a slower 9.1% YoY to ₹45.4 Cr — more than a 10-point gap versus the consolidated PAT growth rate, meaning subsidiaries and export operations, not the parent's core India business, drove the better group-level profit growth. The headline PAT growth also masks a core-margin squeeze. Operating margin (EBITDA excluding other income, on revenue) eased to roughly 6.2% from 6.6% a year ago — even though it improved sequentially from Q1's 4.2% — as material and purchased-goods costs rose to about 56.7% of revenue from 45.6% a year ago, pointing to a costlier project mix this quarter. That squeeze was more than offset below the operating line: other income nearly doubled YoY to ₹12.2 Cr from ₹5.4 Cr, and finance costs fell to ₹3.4 Cr from ₹5.0 Cr, which is what lifted net margin to 2.7% from 2.3% YoY even as core profitability softened. None of this is flagged as exceptional in the filing, so the reported +20.1% YoY PAT growth needs no one-off adjustment — but its quality sits below the operating line, not in it. On the August Q1 FY27 call, management gave no numeric guidance but said international orders (43% of intake) would convert to revenue through Q2–Q4 FY27, and that Praj GenX was targeted for EBITDA breakeven by FY27-end. This quarter is broadly consistent with the first point: overseas revenue jumped to ₹323.8 Cr from ₹177.2 Cr in Q1 (+82.7% QoQ); the GenX breakeven timeline isn't separately disclosed in this filing and remains unverified. No quarter-specific street consensus could be found in available previews, so the print can't be graded against a Street number; full-year FY27 consensus (per market trackers) implies EPS growth near 12%, which this quarter alone neither confirms nor contradicts. No separate management press release accompanied the filing, so there is no company framing to reconcile against the numbers. The quarter's other disclosed development, the mid-September Bio-IBA tie-up with Gevo, remains a developmental initiative per management's own prior characterization with no visible revenue contribution yet.

29 Oct 2026, 04:13 pm

Corporate Events

Board MeetingPRAJIND
2026
29Oct

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingPRAJIND
2026
13Aug

Board Meeting

The 40th Annual General Meeting (AGM) of the Company will be…

BSE Filing ↗
DividendPRAJIND
2026
6Aug

₹3.6 / share

BSE Filing ↗
Board MeetingPRAJIND
2026
28May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing ↗
Board MeetingPRAJIND
2025
31Dec

Board Meeting

Closure of Trading Window

BSE Filing ↗
Board MeetingPRAJIND
2025
30Sep

Board Meeting

Intimation of Closure of Trading Window

BSE Filing ↗
Board MeetingPRAJIND
2024
25Oct

Board Meeting

Consider and approve Un-Audited Financial Results

BSE Filing ↗
Board MeetingPRAJIND
2024
25Jul

Board Meeting

Considering & Adopting Un-audited Financial Results

BSE Filing ↗
Board MeetingPRAJIND
2024
1Jul

Board Meeting

Closure of Trading Window

BSE Filing ↗
Board MeetingPRAJIND
2023
31Oct

Board Meeting

Approve Un-audited Financial Results for second quarter & ha…

BSE Filing ↗
DividendPRAJIND
2023
26Jul

₹4.5 / share

BSE Filing ↗